Ask AI
ProCE Banner Activity

Conference to Clinic: A Test-Your-Knowledge Challenge of Emerging Next-Generation KRAS G12C–Targeted Therapies in NSCLC

Slideset

Downloadable slides on investigational next-generation KRAS G12C–targeted therapies—monotherapies and combination regimens—and rationale for KRAS inhibition in NSCLC.

Released: June 15, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Target Audience

This activity is intended for oncologists, nurse practitioners, physician associates, pharmacists, nurses, and other healthcare professionals who care for patients with non-small-cell lung cancer. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify patients with NSCLC who may be eligible for enrollment on clinical trials with next-generation KRAS G12C–targeted therapies

  • Evaluate how next-generation KRAS G12C–targeted agents in late-phase clinical trials might be integrated into real-world clinical practice for patients with NSCLC

  • Discuss with colleagues and patients ongoing advances in targeting KRAS G12C for solid tumors